Elisabeth Svanberg

Chief Development Officer

Elisabeth Svanberg received her MD and PhD from the University of Gothenburg, and is a board certified general surgeon and associate professor of surgery. She joined Serono International based in Geneva Switzerland in 2000. Initially Elisabeth worked in the field of metabolism, particularly wasting conditions, as a natural continuation of her academic and clinical work. Elisabeth subsequently held roles of increasing responsibilities at Serono/Merck Serono before joining Bristol Myers Squibb (BMS) in the United States in 2007.  At BMS, Elisabeth served as development leader (2007 and 2011) for dapagliflozin (Forxiga/Farxiga), a first in class medicine now registered and launched worldwide to treat type 2 diabetes, and subsequently was Vice President and Head of the Intercontinental Medical Department responsible for Canada, Latin America, Middle East & Africa, Asia Pacific and Australia/New Zealand (2011- 2014). In 2014 Elisabeth joined Janssen Pharmaceuticals (a Johnson & Johnson Company) as Vice President, Head of the Established Products group managing a portfolio of 90 products, used by an estimated 150 million patients globally.